SHANGHAI, Dec. 7, 2025 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced today announced with great pleasure that its independently developed fully human BCMA-targeted CAR-T product, zevorcabtagene autoleucel (zevor-cel,…
Duke has won its first outright Atlantic Coast Conference title since 1962 and thrown the College Football Playoff into chaos. Darian Mensah connected with Jeremiah Hasley for a 1-yard touchdown on a fourth-down play in overtime, and the unranked Blue…
HONG KONG, Dec. 7, 2025 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) announced the successful inclusion of all five of the Company’s self-developed innovative drugs into the updated National Reimbursement Drug List (NRDL) for 2025, released by China’s…
TAIPEI, Dec. 6, 2025 /PRNewswire/ — Skymizer today announced that its next-generation HyperThought™ LLM Accelerator IP has been awarded “Best IP/Processor of the Yearˮ and named the “Most Promising Productˮ at the prestigious EE Awards Asia 2025, hosted by ASPENCORE…
The Virginia State Police and Fairfax County police are asking for the public’s help to find a 78-year-old man in the early stages of dementia who has been missing since Monday, Dec. 1.
New multilingual capabilities expand access to real-time GLP-1 dining guidance as WHO highlights the importance of protein-focused nutrition.
Issued on behalf of GoldHaven Resource Corp.
LEXINGTON, Mass., Dec. 6, 2025 /PRNewswire/ — Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company, announced new data from a post hoc analysis of the Phase 2 eNRGy trial (NCT02912949) evaluating zenocutuzumab in patients with treatment-naïve non-small cell lung…
James Madison has hired former Florida coach Billy Napier to replace Bob Chesney, who is leaving for UCLA but would coach the Dukes in the College Football Playoff if they make the 12-team field. Napier was 22-23 in four seasons…
SHANGHAI, Dec. 6, 2025 /PRNewswire/ — Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, today announced encouraging initial data from an investigator-initiated, first-in-human study of GT801, a T-LNP/mRNA–based in vivo…